Shukra Pharmaceuticals (524632) Q4 25/26 earnings summary

Executive summary

• Audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, were approved, with an unmodified audit opinion from statutory auditors.

• A final dividend of ₹0.01 per equity share was recommended for FY 2025-26, subject to shareholder approval.

• 1,735,000 equity shares were allotted to promoters upon conversion of warrants, increasing paid-up capital.

Financial highlights

• Consolidated revenue from operations for FY 2025-26 was ₹5,672.74 lakhs, up from ₹3,258.73 lakhs year-over-year.

• Consolidated net profit for FY 2025-26 was ₹2,205.84 lakhs, compared to ₹957.51 lakhs in the previous year.

• Standalone revenue for FY 2025-26 was ₹5,670.61 lakhs, with net profit at ₹2,204.79 lakhs, both showing significant year-over-year growth.

• Earnings per share (EPS) for FY 2025-26 stood at ₹0.50 (basic and diluted) on both standalone and consolidated basis.

• Total assets as of March 31, 2026, were ₹11,744.00 lakhs (consolidated), up from ₹8,677.32 lakhs year-over-year.

Outlook and guidance

• No deviation or variation in the utilization of proceeds from preferential issue; funds used as planned for working capital, debt repayment, and capital expenditure.